Histological confirmation of melanoma will be required by previous biopsy or cytology.
Histological confirmation of clear cell renal cancer
Histological confirmation of adenocarcinoma of the prostate within  months of study enrollment
At least one volumetrically measurable and >=  cc NF-related VS (histological confirmation not required)
Histological confirmation of ER negative breast carcinoma (defined as less than %), stage I, II, or III
Evidence of active disease (histological confirmation of reactivation or progression is not required)
Have histological confirmation of breast cancer with recurrent and/or metastatic lesions via investigational site which has failed prior therapy.
Histological confirmation of mycosis fungoides as confirmed by the Mayo Clinic Arizona Dermatopathology Department
Histological confirmation of breast cancer
Have histological confirmation of breast cancer with recurrent and/or metastatic lesions via investigational site.
Histological confirmation of malignancy (primary tumor)
Histological confirmation of malignant carcinoma/sarcoma (any site) with metastasis to lung; histologic confirmation of the lung metastasis is not required providing there has been pathologic confirmation of malignancy
Histological confirmation of cholangiocarcinoma
Has histological confirmation of breast carcinoma.
Histological confirmation of GIST
Patients must have histological confirmation of breast carcinoma
Have histological confirmation of HER positive breast cancer
Patients must have histological confirmation of metastatic urothelial carcinoma; patients must have sufficient tumor tissues for future MTAP testing and research; histological variants such as glandular, squamous, sarcomatoid, micropapillary, plasmacytoid, and small cell changes will not be allowed for this trial unless these tumors are MTAP-deficient
Histological confirmation of pheochromocytoma (PH)/paraganglioma (PG)
Patients must have histological confirmation of metastatic cancer with at least one metastatic or primary lesion in the liver, lung, or adrenal gland
Histological confirmation of SCLC.
Histological confirmation of relapsed/refractory CD positive diffuse large B-cell lymphoma; network sites must submit slides to Roswell Park for central review and confirmation
Patients must have histological confirmation of a cutaneous T-cell lymphoma (CTCL) of any histology; confirmation of histological diagnosis must be completed prior to enrollment by the lead site (Northwestern)\r\n* Patients will be stratified by mycosis fungoides (MF) and Sezary syndrome (SS) (report diagnostic or consistent with MF/SS), stage IA-IVB according to TNM blood (TNMB) classification versus other CTCL histologies
Histological confirmation of adenocarcinoma of the breast
Patients have histological confirmation of invasive breast carcinoma
Histological confirmation of breast carcinoma
Histological confirmation of glioblastoma
histological confirmation of transformation, or
Histological confirmation of thymoma
Histological confirmation of CTCL; a documented verifiable biopsy report is required
Patients must have histological confirmation of a brain tumor at diagnosis or relapse for all tumors
Patients have histological confirmation of breast carcinoma
Histological confirmation of malignancy (primary or metastatic tumor)
Confirmation of:
Subjects with histological confirmation of RCC
Histological confirmation of malignancy (primary or metastatic tumor)
Histological confirmation of breast carcinoma; pathologic evidence of dermal lymphatic invasion should be noted but not required
Prior surgery for a low grade tumor is allowed, provided histological confirmation of anaplastic tumor is present at the time of progression
(. continued) Patients with prior therapy that included interstitial brachytherapy, Gliadel wafers or stereotactic radiosurgical procedures must have confirmation of true progressive disease rather than radiation necrosis. Such confirmation may be using advanced imaging studies (e.g. PET scans, diffusion-perfusion MRI, SPECT etc) or if available, surgical sampling and histological confirmation (surgery is not required).
Histological or cytologic confirmation of unresectable or metastatic cholangiocarcinoma (intrahepatic, hilar, extrahepatic bile duct)
No histological confirmation of breast cancer
Histological confirmation of breast cancer
Histological confirmation of prostate cancer
Histological confirmation of prostate cancer
Histological confirmation of prostate cancer
Tissue confirmation.
